top of page

GRO Biosciences announced a $60 million series B today to help advance its pipeline that is rooted in adding non-standard amino acid (NSAA) chemistries to therapies.

  • blonca9
  • Jul 19, 2024
  • 1 min read

Co-founder and CEO Dan Mandell discusses the company’s approach, and describes how this will allow GRObio to advance its lead program for gout into the clinic to proof of concept, as well as expand the company’s pipeline.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page